The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy
Open accessAbstract
Induction and maintenance of cytotoxic T lymphocyte (CTL) activity specific for a primary endogenous tumor was investigated in vivo. The simian virus 40 T antigen (Tag) expressed under the control of the rat insulin promoter (RIP) induced pancreatic β-cell tumors producing insulin, causing progressive hypoglycemia. As an endogenous tumor antigen, the lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP) was introduced also under the control of the RIP. No significant spontaneous CTL activation against GP was observed. However, LCMV infection induced an antitumor CTL response which efficiently reduced the tumor mass, resulting in temporarily normalized blood glucose levels and prolonged survival of double transgenic RIP(GP × Tag2) mice (137 ± 18 d) as opposed to control RIP-Tag2 mice (88 ± 8 d). Surprisingly, the tumor-specific CTL response was not sustained despite the facts that the tumor cells continued to express MHC class I and LCMV-GP–specific CTLs were present and not tolerized. Subsequent adoptive transfer of virus activated spleen cells into RIP(GP × Tag2) mice further prolonged survival (168 ± 11 d), demonstrating continued expression of the LCMV-GP tumor antigen and MHC class I. The data show that the tumor did not spontaneously induce or maintain an activated CTL response, revealing a profound lack of immunogenicity in vivo. Therefore, repetitive immunizations are necessary for prolonged antitumor immunotherapy. In addition, the data suggest that the risk for induction of chronic autoimmune diseases is limited, which may encourage immunotherapy against antigens selectively but not exclusively expressed by the tumor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D. (1985) · Nature · doi:10.1038/315115a0 · Cited by 1,281
Self-citationImmunity to Methylcholanthrene-Induced Sarcomas
(1957) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/18.6.769 · Cited by 1,229
Tumor Antigens Recognized by T Lymphocytes
Boon, T., Cerottini, J.-C., Van den Eynde, B., van der Bruggen, P., & Van Pel, A. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002005 · Cited by 1,221
Ohashi, P. S., Oehen, S., Buerki, K., Pircher, H., Ohashi, C. T., Odermatt, B., Malissen, B., Zinkernagel, R. M., & Hengartner, H. (1991) · Cell · doi:10.1016/0092-8674(91)90164-t · Cited by 1,173
Self-citationTumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells
Townsend, S. E., & Allison, J. P. (1993) · Science · doi:10.1126/science.7678351 · Cited by 1,136
Chen, L., Ashe, S., Brady, W. A., Hellström, I., Hellström, K. E., Ledbetter, J. A., McGowan, P., & Linsley, P. S. (1992) · Cell · doi:10.1016/s0092-8674(05)80059-5 · Cited by 1,050
Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen
Pircher, H., Bürki, K., Lang, R., Hengartner, H., & Zinkernagel, R. M. (1989) · Nature · doi:10.1038/342559a0 · Cited by 1,019
Self-citationKawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6458 · Cited by 914
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo
Cobbold, S. P., Jayasuriya, A., Nash, A., Prospero, T. D., & Waldmann, H. (1984) · Nature · doi:10.1038/312548a0 · Cited by 863
Implications for immunosurveillance of altered HLA class I phenotypes in human tumours
Garrido, F., Ruiz-Cabello, F., Cabrera, T., Pérez-Villar, J. J., López-Botet, M., Duggan-Keen, M., & Stern, P. L. (1997) · Immunology Today · doi:10.1016/s0167-5699(96)10075-x · Cited by 770
Cited by
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
Glycans in cancer and inflammation — potential for therapeutics and diagnostics
Dube, D. H., & Bertozzi, C. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1751 · Cited by 1,598
Gattinoni, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24480 · Cited by 958
Overwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth-Dreese, F. A., Dellemijn, T. A., Antony, P. A., Spiess, P. J., Palmer, D. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030590 · Cited by 925
Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21583 · Cited by 852
Adoptive immunotherapy for cancer: building on success
Gattinoni, L., Powell, D. J., Rosenberg, S. A., & Restifo, N. P. (2006) · Nature Reviews Immunology · doi:10.1038/nri1842 · Cited by 845
Marchand, M., van Baren, N., Weynants, P., Brichard, V., Dr�no, B., Tessier, M.-H., Rankin, E., Parmiani, G., Arienti, F., Humblet, Y., et al. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990118)80:2<219::aid-ijc10>3.0.co;2-s · Cited by 784
Does the Immune System See Tumors as Foreign or Self?
Pardoll, D. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141135 · Cited by 753
Immunotherapy of Tumors with Autologous Tumor-Derived Heat Shock Protein Preparations
Tamura, Y., Peng, P., Liu, K., Daou, M., & Srivastava, P. K. (1997) · Science · doi:10.1126/science.278.5335.117 · Cited by 680
The role of CD4+ T cell responses in antitumor immunity
Pardoll, D. M., & Topalian, S. L. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80228-8 · Cited by 672
Targeting tumours with genetically enhanced T lymphocytes
Sadelain, M., Rivière, I., & Brentjens, R. (2003) · Nature Reviews Cancer · doi:10.1038/nrc971 · Cited by 535
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
Smith, B. A. H., & Bertozzi, C. R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00093-1 · Cited by 500
Immune surveillance against a solid tumor fails because of immunological ignorance
Ochsenbein, A. F., Klenerman, P., Karrer, U., Ludewig, B., Pericin, M., Hengartner, H., & Zinkernagel, R. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2233 · Cited by 453
Self-citationMelcher, A., Todryk, S., Hardwick, N., Ford, M., Jacobson, M., & Vile, R. G. (1998) · Nature Medicine · doi:10.1038/nm0598-581 · Cited by 445
Pardoll, D. M. (1998) · Nature Medicine · doi:10.1038/nm0598supp-525 · Cited by 428
Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection
Friberg, M., Jennings, R., Alsarraj, M., Dessureault, S., Cantor, A., Extermann, M., Mellor, A. L., Munn, D. H., & Antonia, S. J. (2002) · International Journal of Cancer · doi:10.1002/ijc.10645 · Cited by 365
Spinning molecular immunology into successful immunotherapy
Pardoll, D. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri774 · Cited by 360
Prostate cancer as a model for tumour immunotherapy
Drake, C. G. (2010) · Nature Reviews Immunology · doi:10.1038/nri2817 · Cited by 347
Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks
Peixoto, A., Relvas-Santos, M., Azevedo, R., Santos, L. L., & Ferreira, J. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00380 · Cited by 334
Workshop R: Tumor Immunology, Abstract R1 bis R30
(2001) · Immunobiology · doi:10.1016/s0171-2985(04)70018-2 · Cited by 312
Tumor-Associated CD8+ T Cell Tolerance Induced by Bone Marrow-Derived Immature Myeloid Cells
Kusmartsev, S., Nagaraj, S., & Gabrilovich, D. I. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.7.4583 · Cited by 310
Müller-Hermelink, N., Braumüller, H., Pichler, B., Wieder, T., Mailhammer, R., Schaak, K., Ghoreschi, K., Yazdi, A., Haubner, R., Sander, C. A., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.04.001 · Cited by 302
The promise of cancer vaccines
Gilboa, E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1359 · Cited by 267
Zhu, L. X., Sharma, S., Stolina, M., Gardner, B., Roth, M. D., Tashkin, D. P., & Dubinett, S. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.1.373 · Cited by 252
Ludewig, B., Ochsenbein, A. F., Odermatt, B., Paulin, D., Hengartner, H., & Zinkernagel, R. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.5.795 · Cited by 252
Self-citationTracking T cells with tetramers: new tales from new tools
Klenerman, P., Cerundolo, V., & Dunbar, P. R. (2002) · Nature Reviews Immunology · doi:10.1038/nri777 · Cited by 190
Gene Therapy to Manipulate Effector T Cell Trafficking to Tumors for Immunotherapy
Gough, M., Crittenden, M., Thanarajasingam, U., Sanchez-Perez, L., Thompson, J., Jevremovic, D., & Vile, R. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.9.5766 · Cited by 60
“Similar results have been seen in many models in which large numbers of transgenic or in vitro-derived activated CTLs do not consistently cause regression of tumors (2, 3).”
Result
Metadata
- Authors
- Speiser, D. E., Miranda, R., Zakarian, A., Bachmann, M. F., McKall-Faienza, K., Odermatt, B., Hanahan, D., Zinkernagel, R. M., & Ohashi, P. S.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1997-08-29
- Volume
- 186
- Issue
- 5
- Pages
- 645-653
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W1983467545
- Cited by
- 309
- References
- 37
- FWCI
- 9.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.